Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Jan-Feb;6(1):15-7.
doi: 10.4161/mabs.27436.

Antibody-drug conjugates: present and future

Alain Beck  1 , Janice M Reichert  2
Affiliations
Editorial

Antibody-drug conjugates: present and future

Alain Beck et al. MAbs. 2014 Jan-Feb.

Abstract

Antibody-drug conjugates (ADCs) are becoming an increasingly important sub-class of antibody-related therapeutics. Two ADCs, brentuximab vedotin (Adcetris) and ado-trastuzumab emtansine (Kadcyla), were recently approved for marketing both by the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA). Brentuximab vedotin is marketed as therapy for hematological malignancies (Hodgkin lymphoma, systemic anaplastic large cell lymphoma), while ado-trastuzumab emtansine is marketed for treatment of a solid tumor (breast cancer). The approvals of these two ADCs followed the mitigated success of gemtuzumab ozogamicin (Mylotarg), which was withdrawn from the US market in 2010, ten years after approval by the FDA.

PubMed Disclaimer

Figures

None
Figure 1. Novel antibody-drug conjugates entering clinical study during 2009?2013. Data available as of November 2013.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Beck A, Haeuw JF, Wurch T, Goetsch L, Bailly C, Corvaïa N. . The next generation of antibody-drug conjugates comes of age. Discov Med 2010; 10:329 - 39; PMID: 21034674 - PubMed
    1. Reichert JM. . Antibodies to watch in 2014. MAbs 2013; 6; In press PMID: 24284914 - PMC - PubMed
    1. Wagner-Rousset E, Janin-Bussat MC, Colas O, Excoffier M, Haeuw JF, Rilatt I, Perez M, Corvaïa N, Beck A. . Antibody Drug Conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. MAbs 2013; 6; Forthcoming 2013 PMID: 24135617 - PMC - PubMed
    1. Beck A. Review of Antibody-Drug Conjugates, Methods in Molecular Biology series: A book edited by Laurent Ducry, mAbs 2014; 6: in press.
    1. Beck A, Wurch T, Bailly C, Corvaïa N. . Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345 - 52; http://dx.doi.org/10.1038/nri2747; PMID: 20414207 - DOI - PubMed

Publication types

MeSH terms